Numerous studies have shown that high expression of ETV4 in prostate cancer (51), breast cancer (52), colorectal cancer (53), pancreatic cancer (54), and cholangiocarcinoma (55) often correlates with poor prognosis. Here, ETV4 is linked to breast cancer.